Trial Profile

A Clinical Study Evaluating the Safety and Efficacy of Universal CD19-Targeted CAR-T (UWD-CD19) Therapy for Refractory and Relapsed B-Cell Tumors

Status: Suspended

Phase of Trial: Phase 0

Latest Information Update: 17 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REVO UWD 19 (Primary)
Indications B-cell lymphoma
Focus Adverse reactions
Sponsors Wondercel Therapeutics

Most Recent Events

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
07 May 2026 Status changed from recruiting to suspended for the implementation of the new regulation policy by the Chinese authority.
04 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com